The United States administration has recently ordered $290 million worth of a drug called Nplate, which can be used to treat radiation sickness.
Newsweek reported that early this month, the US Department for Health and Human Services, or HHS, announced it was purchasing a supply of the drug Nplate as part of long-standing, ongoing initiatives to better be ready to save lives after radiological and nuclear emergencies.
I have a question, WHY is our government stocking up on an anti-radiation medicine for $300 million and a shelf life of less than 2 yrs that the producer said they've NEVER supplied the government with it before?!?https://t.co/0MfCwDDTgL
— See What I'm Sayin (@WstCstPatriot) October 11, 2022
Essentially, Nplate is a prescription drug manufactured by California-based biotechnology firm Amgen. Meaning, it is not available for purchase over the counter. The company said its drug is administered as an injection by a healthcare provider.
Amgen also said that the drug is developed to treat low blood platelet counts because of a condition called "immune thrombocytopenia," and not a low platelet count caused by any other condition.
